BERKELEY, Calif.--(BUSINESS WIRE)--Jan. 19, 2006--Bayer HealthCare, LLC., announced today that Kogenate(R) FS (Antihemophilic Factor (Recombinant), Formulated with Sucrose), its recombinant factor VIII hemophilia A treatment, is now available with BIO-SET(R) needleless reconstitution system in the United States. Approved by the United States Food and Drug Administration (FDA), BIO-SET(R) is the first and only integrated reconstitution system for recombinant factor VIII that reduces the risk of accidental needle-stick injuries during reconstitution.
